Table 2 Univariate and multivariate Cox regression analyses for progression-free survival and overall survival of melanoma patients and multiplex RT-qPCR immunotherapy panel markers

From: Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma

Variable (HI/LO)	PFS				OS
	Univariate analysis		Multivariate^a analysis		Univariate analysis		Multivariate* analysis
	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value
A
CD274	0.48 (0.29–0.81)	0.0053	0.57 (0.32–1.03)	0.0632	0.29 (0.13–0.58)	0.0004	0.30 (0.13–0.66)	0.0024
PDCD1LG2	0.47 (0.27–0.79)	0.0044	0.49 (0.27–0.89)	0.0179	0.56 (0.28–1.09)	0.0936	0.52 (0.24–1.11)	0.0922
CD8A	0.36 (0.21–0.61)	0.0001	0.39 (0.22–0.68)	0.0009	0.38 (0.18–0.75)	0.0051	0.40 (0.18–0.84)	0.0152
IRF1	0.47 (0.28–0.78)	0.0035	0.48 (0.26–0.86)	0.0135	0.41 (0.20–0.80)	0.0094	0.36 (0.16–0.79)	0.0109
B
CD274 & PDCD1LG2	0.30 (0.16–0.57)	< 0.0001	0.31 (0.14–0.59)	0.0003	0.38 (0.19–0.73)	0.0043	0.41 (0.19–0.86)	0.0192

^aCox proportional hazards model included age, sex, mutation status, stage, treatment, and prior immune checkpoint blockade as covariates
P values highlighted in bold are statistically significant

Back to article page